Company: SMNR
Filing Date: 2025-04-02
Form Type: 10-K
Source: 0001213900-25-027319
Chunk: 737

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-04-02
Form: 10-K
Item: Item 4
Chunk 737
---
 trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (1,968,370) 
     (1,968,370)
  
    Balance
    as of December 31, 2024 
     510,000  
     51  
     2,062,500  
     206  
    $(10,417,973) 
     (10,417,716)

    For
    the Year Ended December 31, 2023 

    Class
    A Ordinary Shares  
    Class
    B Ordinary Shares  
    Accumulated  
    Shareholders’ 

    Shares  
    Amount  
    Shares  
    Amount  
    Deficit  
    Deficit 
  
    Balance
    as of December 31, 2022 
     510,000  
    $    51  
     2,062,500  
    $206  
    $(3,271,562) 
    $     (3,271,305)
  
    Net
    income 
     -  
     -  
     -  
     -  
     632,536  
     632,536 
  
    Subsequent
    measurement of ordinary shares subject to possible redemption (interest earned on trust account and extension deposit) 
     -  
     -  
     -  
     -  
     (5,643,271) 
     (5,643,271)
  
    Balance
    as of December 31, 2023 
     510,000  
    $51  
    $2,062,500  
    $206  
    $(8,282,297) 
    $(8,282,040)

The
accompanying notes are an integral part of these consolidated financial statements.

F-6

DENALI
CAPITAL ACQUISITION CORP.

CONSOLIDATED
STATEMENTS OF CASH FLOWS

    For the  
    For the 

    Year Ended  
    Year Ended 

    December 31,  2024  
    December 31,  2023 
  
    Cash flows from operating activities: 

    Net (loss)/income 
    $(167,306)